Multipl Sklerozda Prognoz ve Mortalite

Carotenuto A, Di Monaco C, Papetti L, et al. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod. J Neurol. 2024;271(10):6773-6781.

Jakimovski D, Awan S, Eckert SP, Farooq O, Weinstock-Guttman B. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs. 2022;36(1):45-59.

Portaccio E, Magyari M, Havrdova EK, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977. Published 2024 Aug 22.

Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, et al. Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol. 2021;78(6):726–735.

Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis. Mult Scler Relat Disord. 2020;44:102260.

Huppke B, Ellenberger D, Rosewich H, et al. Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol. 2014; 21(3): 441–446.

Ruggieri M, Iannetti P, Polizzi A, et al. Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004; 25 Suppl 4: S326–S335.

Brola W, Steinborn B. Pediatric multiple sclerosis - current status of epidemiology, diagnosis and treatment. Neurol Neurochir Pol. 2020;54(6):508-517.

Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B, et al. Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure. Mult Scler. 2019;25(7):927–936.

Wallach AI, Waltz M, Casper TC, Aaen G, Belman A, Benson L, et al. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. 2020;26(14):1938–1947.

Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018; 18(1): 27.

Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014; 3(2): 186–193.

Renoux C, Vukusic S, Confavreux C, et al. Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007; 356(25): 2603–2613.

Miller D, Leary S. Primary-progressive multiple sclerosis. The Lancet Neurology. 2007; 6(10): 903–912.

Galardi MM, Gaudioso C, Ahmadi S, et al. Differential Diagnosis of Pediatric Multiple Sclerosis. Children (Basel). 2019; 6(6).

Mikaeloff Y, Suissa S, Vallée L, et al. KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004; 144(2): 246–252.

Langille MM, Rutatangwa A, Francisco C. Pediatric Multiple Sclerosis: A Review. Adv Pediatr. 2019;66:209-229.

Till C, Noguera A, Verhey LH, et al. Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. J Int Neuropsychol Soc. 2016; 22(10): 1050–1060.

Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005; 64(5): 891–894

Amato MP, Goretti B, Ghezzi A, et al. MS Study Group of the Italian Neurological Society. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014; 83(16): 1432–1438.

Cardoso M, Olmo NR, Fragoso YD. Systematic Review of Cognitive Dysfunction in Pediatric and Juvenile Multiple Sclerosis. Pediatr Neurol. 2015; 53(4): 287–292.

Margoni M, Preziosa P, Rocca MA, Filippi M. Pediatric multiple sclerosis: developments in timely diagnosis and prognostication. Expert Rev Neurother. 2022;22(5):393-403.

Van der Vuurst de Vries RM, Wong YYM, Mescheriakova JY, et al. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. Mult Scler. 2019;25(7):958-967.

Smyrke N, Dunn N, Murley C, Mason D. Standardized mortality ratios in multiple sclerosis: Systematic review with meta-analysis. Acta Neurol Scand. 2022;145(3):360-370.

Sumelahti ML, Verkko A, Kytö V, Sipilä JOT. Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010. Eur J Neurol. 2024;31(12):e16480.

Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry. 2016;87(3):324-331.

Leray E, Vukusic S, Debouverie M, et al. Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale French observational study. PLoS One. 2015;10(7):e0132033.

Willumsen JS, Grytten N, Aarseth J, Myklebust TÅ, Myhr KM, Midgard R. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry‐based linkage study. J Neurol Neurosurg Psychiatry. 2022;93:1154‐1161.

Ng HS, Zhu F, Kingwell E, et al. Disease‐modifying drugs for multiple sclerosis and association with survival. Neurol Neuroimmunol Neuroinflamm. 2022;9:e200005.

Ragonese P, Aridon P, Salemi G, D'Amelio M, Savettieri G. Mortality in multiple sclerosis: a review. Eur J Neurol. 2008;15(2):123-127.

Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020; 11: 851.

Muhtaroglu M, Ertugrul Mut S, Selcuk F, Malkoc M. Evaluation of respiratory functions and quality of life in multiple sclerosis patients. Acta Neurol Belg. 2020; 120(5): 1107-1113.

Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017; 23(7): 923-927.

Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012; 73(6): 411-417.